Webinar: Healthcare’s next big wave: Why everyone should be thinking about cell and gene therapy

Aug 4, 2022
Survey the impact of CGT market growth on the healthcare system, HCP referrals and wider pharma.

Survey the impact of CGT market growth on the healthcare system, HCP referrals and wider pharma. Despite its novelty, cell and gene therapy is already sending shock waves across pharma. The innovative technology it employs promises many patients with debilitating illnesses a cure, and for this reason, many hope CGT will soon become a frontline therapy. Yet as more products gain approval quickly and the industry expands, navigating the CGT space will bring critical challenges. While market access and commercialization teams with a lack of experience in the space struggle to stabilize and scale up delivery networks, access and reimbursement models, the healthcare system will need to adjust to the operational toll of expansion. So, what can pharma do to avoid this functional disaster? CGT companies must stay diligent, adapt to a saturated market and learn how to stand out from their competitors to avoid getting left behind and ensure patients benefit from all of CGT’s potential gains. That’s why Reuters Events are convening experts from ASC Therapeutics, bluebird bio, Iovance and Legend Biotech to ensure you’re prepared for the future of CGT expansion. Join our exclusive discussion on the 29th June at 10am EST to gain vital insights on their predictions for what the cell and gene market will look like upon its expansion and how this will alter other elements of pharma at large to create a new future for CGT. Learnings will include: • How to utilize cell and gene therapy industry forecasting to accommodate for and aid the process of internal scalability and upgrading commercial skillsets. • What both people within and outside the industry, such as hospitals, treatment centers and CMO’s, will have to do to prepare to ensure they’re able to adapt to the changing shape of pharma so they don’t get left behind. • What indicators industry leaders use to measure sector success and how the predicted growth of the advanced therapy sector will influence healthcare providers, referrals, and pharma at large • Explore what the future of CGT may mean for your commercial, market access, medical affairs, manufacturing, regulatory or reimbursement role in traditional pharma and understand how industry change will affect your day-to-day tasks.

Please login to view video - or subscribe here

Survey the impact of CGT market growth on the healthcare system, HCP referrals and wider pharma.

Despite its novelty, cell and gene therapy is already sending shock waves across pharma. The innovative technology it employs promises many patients with debilitating illnesses a cure, and for this reason, many hope CGT will soon become a frontline therapy. Yet as more products gain approval quickly and the industry expands, navigating the CGT space will bring critical challenges. While market access and commercialization teams with a lack of experience in the space struggle to stabilize and scale up delivery networks, access and reimbursement models, the healthcare system will need to adjust to the operational toll of expansion.

So, what can pharma do to avoid this functional disaster? CGT companies must stay diligent, adapt to a saturated market and learn how to stand out from their competitors to avoid getting left behind and ensure patients benefit from all of CGT’s potential gains.

That’s why Reuters Events are convening experts from ASC Therapeutics, bluebird bio, Iovance and Legend Biotech to ensure you’re prepared for the future of CGT expansion. Join our exclusive discussion on the 29th June at 10am EST to gain vital insights on their predictions for what the cell and gene market will look like upon its expansion and how this will alter other elements of pharma at large to create a new future for CGT.

Learnings will include:
• How to utilize cell and gene therapy industry forecasting to accommodate for and aid the process of internal scalability and upgrading commercial skillsets.
• What both people within and outside the industry, such as hospitals, treatment centers and CMO’s, will have to do to prepare to ensure they’re able to adapt to the changing shape of pharma so they don’t get left behind.
• What indicators industry leaders use to measure sector success and how the predicted growth of the advanced therapy sector will influence healthcare providers, referrals, and pharma at large
• Explore what the future of CGT may mean for your commercial, market access, medical affairs, manufacturing, regulatory or reimbursement role in traditional pharma and understand how industry change will affect your day-to-day tasks.

comments powered by Disqus